TGA investigates possible myocarditis link to Nuvaxovid
Health authorities in the US have also raised concerns, but the manufacturer says there is no evidence of a causal relationship
Doctors are being alerted to a potential excess risk of myocarditis with the protein-based vaccine Nuvaxovid following reports of suspected cases.
Although an increased risk of heart inflammation has been established with mRNA vaccines, the risk with Nuvaxovid, made by Novavax, remains unknown.
The TGA says it has received a small number of reports of suspected cardiac adverse events among the 726 adverse event reports following Nuvaxovid inoculation and is actively investigating a potential association with the vaccine.
“Three cases were likely to represent myocarditis, and 11 were likely to represent pericarditis,” the watchdog said.
